Intra Cellular Therapies reported $18.01M in Gross Profit on Sales for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US $ 110.02M 8.15M
Biocryst Pharmaceuticals BCRX:US $ 49.62M 36.44M
Biogen BIIB:US $ 2267.1M 48.2M
Bristol Myers Squibb BMY:US $ 9252M 682M
Esperion Therapeutics ESPR:US $ 38.86M 32.66M
Gilead Sciences GILD:US $ 4827M 235M
Gw Pharmaceuticals GWPH:US $ 140.66M 2.86M
Halozyme Therapeutics HALO:US $ 113.44M 42.63M
Intra Cellular Therapies ITCI:US $ 18.01M 3.58M
JAZZ PHA JAZZ:US $ 632.62M 65.22M
Johnson & Johnson JNJ:US $ 16088M 343M
Nektar Therapeutics NKTR:US $ 20.66M 2.77M
Neurocrine Biosciences NBIX:US $ 285.8M 52.1M
Novartis NVS:US $ 9540M 679M
Redhill Biopharma RDHL:US $ 10.91M 0.59M
Supernus Pharmaceuticals SUPN:US $ 116.3M 0.32M
United Therapeutics UTHR:US $ 409.3M 53.2M
Vanda Pharmaceuticals VNDA:US $ 61.33M 4.69M
Zogenix ZGNX:US $ 17.57M 4.56M